18 Jun 2013 15:23
18 June 2013
Plethora Solutions Holdings PLC
("Plethora" or the "Company")
Annual Financial Report for the year ended 31 December 2012 and Notice of AGM
Further to the Company's announcement on 7 June 2013, Plethora Solutions Holdings plc (AIM: PLE) posted its annual report to shareholders on 7 June 2013 together with the notice of the 2013 Annual General Meeting ("AGM") of the Company and form of proxy.
The Annual Report and Accounts for the year ended 31 December 2012 and Notice of AGM are now available on the Company's website at www.plethorasolutions.co.uk.
-Ends-
Enquiries:
Plethora Solutions Ronald Openshaw, CEO | Tel : +44(0) 20 3077 5400 |
Daniel Stewart (Nomad & Joint Broker) David Hart / James Felix (Nomad) Martin Lampshire (Broker) | Tel : +44 (0) 20 7776 6550
|
Hybridan LLP (Joint Broker) Claire Louise Noyce/ Deepak Reddy | Tel: +44 (0) 20 7947 4350
|
Britton Financial PR Tim Blackstone | Tel: + 44 (0) 20 7241 9786 + 44 (0) 7957 140416 |
About Plethora:
Plethora is headquartered in the UK and is listed on the London Stock Exchange (AIM: PLE.L). Further information is available at www.plethorasolutions.co.uk
Plethora is focussed on seeking to launchPSD502 for the treatment of premature ejaculation.
About PSD502 & Premature Ejaculation:
PSD502 is a topical spray for the treatment of premature ejaculation containing lidocaine and prilocaine in a eutectic-like mixture. The product has completed all clinical testing and has been submitted for approval in Europe with the EMA. The Company anticipates launch in late 2013 or early 2014.
Premature ejaculation is possibly the most common form of sexual dysfunction in men. Epidemiological studies conducted in the US and in Europe indicate a prevalence of 20 - 30% in men of all ages. There is currently no globally approved and effective pharmaceutical treatment for this condition.
In the absence of any widely approved pharmaceutical therapy with good patient acceptance, the premature ejaculation market offers significant potential for development and growth. An effective drug therapy for premature ejaculation may have a comparable commercial potential to the erectile dysfunction drugs.